BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 36625657)

  • 61. Humoral immunity to SARS-CoV-2 and seasonal coronaviruses in children and adults in north-eastern France.
    Woudenberg T; Pelleau S; Anna F; Attia M; Donnadieu F; Gravet A; Lohmann C; Seraphin H; Guiheneuf R; Delamare C; Stefic K; Marlet J; Brochot E; Castelain S; Augereau O; Sibilia J; Dubos F; Meddour D; Guen CG; Coste-Burel M; Imbert-Marcille BM; Chauvire-Drouard A; Schweitzer C; Gatin A; Lomazzi S; Joulié A; Haas H; Cantais A; Bertholon F; Chinazzo-Vigouroux MF; Abdallah MS; Arowas L; Charneau P; Hoen B; Demeret C; Werf SV; Fontanet A; White M
    EBioMedicine; 2021 Aug; 70():103495. PubMed ID: 34304047
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Boosting of cross-reactive antibodies to endemic coronaviruses by SARS-CoV-2 infection but not vaccination with stabilized spike.
    Crowley AR; Natarajan H; Hederman AP; Bobak CA; Weiner JA; Wieland-Alter W; Lee J; Bloch EM; Tobian AAR; Redd AD; Blankson JN; Wolf D; Goetghebuer T; Marchant A; Connor RI; Wright PF; Ackerman ME
    Elife; 2022 Mar; 11():. PubMed ID: 35289271
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Prevalence of antibodies to four human coronaviruses is lower in nasal secretions than in serum.
    Gorse GJ; Patel GB; Vitale JN; O'Connor TZ
    Clin Vaccine Immunol; 2010 Dec; 17(12):1875-80. PubMed ID: 20943876
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Seroprevalence of four endemic human coronaviruses and, reactivity and neutralization capability against SARS-CoV-2 among children in the Philippines.
    Sayama Y; Okamoto M; Saito M; Saito-Obata M; Tamaki R; Joboco CD; Lupisan S; Oshitani H
    Sci Rep; 2023 Feb; 13(1):2310. PubMed ID: 36759702
    [TBL] [Abstract][Full Text] [Related]  

  • 65. SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19.
    Braun J; Loyal L; Frentsch M; Wendisch D; Georg P; Kurth F; Hippenstiel S; Dingeldey M; Kruse B; Fauchere F; Baysal E; Mangold M; Henze L; Lauster R; Mall MA; Beyer K; Röhmel J; Voigt S; Schmitz J; Miltenyi S; Demuth I; Müller MA; Hocke A; Witzenrath M; Suttorp N; Kern F; Reimer U; Wenschuh H; Drosten C; Corman VM; Giesecke-Thiel C; Sander LE; Thiel A
    Nature; 2020 Nov; 587(7833):270-274. PubMed ID: 32726801
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Diverse Humoral Immune Responses in Younger and Older Adult COVID-19 Patients.
    Sasson JM; Campo JJ; Carpenter RM; Young MK; Randall AZ; Trappl-Kimmons K; Oberai A; Hung C; Edgar J; Teng AA; Pablo JV; Liang X; Yee A; Petri WA; Camerini D
    mBio; 2021 Jun; 12(3):e0122921. PubMed ID: 34182775
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Risk Factors for Healthcare Personnel Infection With Endemic Coronaviruses (HKU1, OC43, NL63, 229E): Results from the Respiratory Protection Effectiveness Clinical Trial (ResPECT).
    Cummings DAT; Radonovich LJ; Gorse GJ; Gaydos CA; Bessesen MT; Brown AC; Gibert CL; Hitchings MDT; Lessler J; Nyquist AC; Rattigan SM; Rodriguez-Barradas MC; Price CS; Reich NG; Simberkoff MS; Perl TM
    Clin Infect Dis; 2021 Dec; 73(11):e4428-e4432. PubMed ID: 32645144
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Neutralizing COVID-19 Convalescent Plasma in Adults Hospitalized With COVID-19: A Blinded, Randomized, Placebo-Controlled Trial.
    Self WH; Wheeler AP; Stewart TG; Schrager H; Mallada J; Thomas CB; Cataldo VD; O'Neal HR; Shapiro NI; Higgins C; Ginde AA; Chauhan L; Johnson NJ; Henning DJ; Jaiswal SJ; Mammen MJ; Harris ES; Pannu SR; Laguio-Vila M; El Atrouni W; de Wit M; Hoda D; Cohn CS; McWilliams C; Shanholtz C; Jones AE; Raval JS; Mucha S; Ipe TS; Qiao X; Schrantz SJ; Shenoy A; Fremont RD; Brady EJ; Carnahan RH; Chappell JD; Crowe JE; Denison MR; Gilchuk P; Stevens LJ; Sutton RE; Thomsen I; Yoder SM; Bistran-Hall AJ; Casey JD; Lindsell CJ; Wang L; Pulley JM; Rhoads JP; Bernard GR; Rice TW;
    Chest; 2022 Nov; 162(5):982-994. PubMed ID: 35780813
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Longitudinal analysis of SARS-CoV-2 antibodies in 8000 U.S. first-time convalescent plasma donations.
    Karbiener M; Farcet MR; Ilk R; Schreiner J; Lenart J; Powers N; Stewart JM; Tallman H; Kreil TR
    Transfusion; 2021 Apr; 61(4):1141-1147. PubMed ID: 33615484
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Neurologic sequelae of COVID-19 are determined by immunologic imprinting from previous coronaviruses.
    Spatola M; Nziza N; Jung W; Deng Y; Yuan D; Dinoto A; Bozzetti S; Chiodega V; Ferrari S; Lauffenburger DA; Mariotto S; Alter G
    Brain; 2023 Oct; 146(10):4292-4305. PubMed ID: 37161609
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.
    Valk SJ; Piechotta V; Chai KL; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2020 May; 5(5):CD013600. PubMed ID: 32406927
    [TBL] [Abstract][Full Text] [Related]  

  • 72. IgG Against Human Betacoronavirus Spike Proteins Correlates With SARS-CoV-2 Anti-Spike IgG Responses and COVID-19 Disease Severity.
    Wang J; Li D; Cameron A; Zhou Q; Wiltse A; Nayak J; Pecora ND; Zand MS
    J Infect Dis; 2022 Aug; 226(3):474-484. PubMed ID: 35091739
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Characterization of pathogen-inactivated COVID-19 convalescent plasma and responses in transfused patients.
    Weisser M; Khanna N; Hedstueck A; Sutter ST; Roesch S; Stehle G; Sava M; Deigendesch N; Battegay M; Infanti L; Holbro A; Bassetti S; Pargger H; Hirsch HH; Leuzinger K; Kaiser L; Vu DL; Baur K; Massaro N; Busch MP; Simmons G; Stone M; Felgner PL; de Assis RR; Khan S; Tsai CT; Robinson PV; Seftel D; Irsch J; Bagri A; Buser AS; Corash L
    Transfusion; 2022 Oct; 62(10):1997-2011. PubMed ID: 36054476
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection.
    Gharbharan A; Jordans CCE; GeurtsvanKessel C; den Hollander JG; Karim F; Mollema FPN; Stalenhoef-Schukken JE; Dofferhoff A; Ludwig I; Koster A; Hassing RJ; Bos JC; van Pottelberge GR; Vlasveld IN; Ammerlaan HSM; van Leeuwen-Segarceanu EM; Miedema J; van der Eerden M; Schrama TJ; Papageorgiou G; Te Boekhorst P; Swaneveld FH; Mueller YM; Schreurs MWJ; van Kampen JJA; Rockx B; Okba NMA; Katsikis PD; Koopmans MPG; Haagmans BL; Rokx C; Rijnders BJA
    Nat Commun; 2021 May; 12(1):3189. PubMed ID: 34045486
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Correlation between Clinical Characteristics and Antibody Levels in COVID-19 Convalescent Plasma Donor Candidates.
    Uzun G; Müller R; Althaus K; Becker M; Marsall P; Junker D; Nowak-Harnau S; Schneiderhan-Marra N; Klüter H; Schrezenmeier H; Bugert P; Bakchoul T
    Viruses; 2023 Jun; 15(6):. PubMed ID: 37376656
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Serological responses in patients with severe acute respiratory syndrome coronavirus infection and cross-reactivity with human coronaviruses 229E, OC43, and NL63.
    Chan KH; Cheng VC; Woo PC; Lau SK; Poon LL; Guan Y; Seto WH; Yuen KY; Peiris JS
    Clin Diagn Lab Immunol; 2005 Nov; 12(11):1317-21. PubMed ID: 16275947
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Etiology and clinical characteristics of SARS-CoV-2 and other human coronaviruses among children in Zhejiang Province, China 2017-2019.
    Zhang Y; Su L; Chen Y; Yu S; Zhang D; Mao H; Fang L
    Virol J; 2021 Apr; 18(1):89. PubMed ID: 33931105
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The prospect of universal coronavirus immunity: characterization of reciprocal and non-reciprocal T cell responses against SARS-CoV2 and common human coronaviruses.
    Soni MK; Migliori E; Fu J; Assal A; Chan HT; Pan J; Khatiwada P; Ciubotariu R; May MS; Pereira MR; De Giorgi V; Sykes M; Mapara MY; Muranski PJ
    Front Immunol; 2023; 14():1212203. PubMed ID: 37901229
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Persistence of Anti-SARS-CoV-2 Antibodies in Long Term Care Residents Over Seven Months After Two COVID-19 Outbreaks.
    Tanunliong G; Liu A; Vijh R; Pidduck T; Kustra J; Márquez AC; Choi A; McLennan M; Hayden A; Kearney C; Gantt S; Krajden M; Morshed M; Jassem AN; Sekirov I
    Front Immunol; 2021; 12():775420. PubMed ID: 35046939
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Impact of Convalescent Plasma Therapy on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Profile in Coronavirus Disease 2019 (COVID-19) Patients.
    Tang J; Grubbs G; Lee Y; Golding H; Khurana S
    Clin Infect Dis; 2022 Jan; 74(2):327-334. PubMed ID: 33861337
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.